WO2016065323A3 - Anticorps à domaine unique dirigés contre des antigènes intracellulaires - Google Patents

Anticorps à domaine unique dirigés contre des antigènes intracellulaires Download PDF

Info

Publication number
WO2016065323A3
WO2016065323A3 PCT/US2015/057223 US2015057223W WO2016065323A3 WO 2016065323 A3 WO2016065323 A3 WO 2016065323A3 US 2015057223 W US2015057223 W US 2015057223W WO 2016065323 A3 WO2016065323 A3 WO 2016065323A3
Authority
WO
WIPO (PCT)
Prior art keywords
sdabs
directed against
domain antibodies
against intracellular
compositions
Prior art date
Application number
PCT/US2015/057223
Other languages
English (en)
Other versions
WO2016065323A2 (fr
Inventor
Sunanda SINGH
Original Assignee
Singh Biotechnology, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to BR112017008165A priority Critical patent/BR112017008165B8/pt
Priority to PL15853465T priority patent/PL3209685T3/pl
Priority to RU2017116710A priority patent/RU2017116710A/ru
Priority to KR1020197026708A priority patent/KR102207381B1/ko
Priority to RS20190750A priority patent/RS59063B1/sr
Priority to EP19165430.0A priority patent/EP3590962B1/fr
Priority to CN201580056968.9A priority patent/CN106852148B/zh
Priority to DK15853465.1T priority patent/DK3209685T3/da
Priority to AU2015335600A priority patent/AU2015335600B2/en
Priority to PL19165430T priority patent/PL3590962T3/pl
Priority to SI201530789T priority patent/SI3209685T1/sl
Priority to JP2017521577A priority patent/JP2017538671A/ja
Priority to ES15853465T priority patent/ES2731876T3/es
Priority to BR122020006918A priority patent/BR122020006918B8/pt
Priority to IL289769A priority patent/IL289769B2/en
Priority to EP21192390.9A priority patent/EP4006052A1/fr
Priority to KR1020177006630A priority patent/KR101831123B1/ko
Application filed by Singh Biotechnology, Llc filed Critical Singh Biotechnology, Llc
Priority to LTEP15853465.1T priority patent/LT3209685T/lt
Priority to EP15853465.1A priority patent/EP3209685B1/fr
Priority to BR122020006907A priority patent/BR122020006907B8/pt
Priority to MX2017003268A priority patent/MX2017003268A/es
Priority to KR1020197026711A priority patent/KR102207382B1/ko
Priority to CA2962275A priority patent/CA2962275C/fr
Priority to BR122020006914A priority patent/BR122020006914B8/pt
Priority to KR1020187004337A priority patent/KR102023289B1/ko
Priority to CN202010738353.7A priority patent/CN111848793B/zh
Publication of WO2016065323A2 publication Critical patent/WO2016065323A2/fr
Publication of WO2016065323A3 publication Critical patent/WO2016065323A3/fr
Priority to IL250961A priority patent/IL250961B/en
Priority to HRP20191056TT priority patent/HRP20191056T1/hr
Priority to AU2019204614A priority patent/AU2019204614B2/en
Priority to CY20191100706T priority patent/CY1122035T1/el
Priority to AU2021200416A priority patent/AU2021200416B2/en
Priority to CY20211101082T priority patent/CY1124867T1/el
Priority to AU2022204167A priority patent/AU2022204167A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4208—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig
    • C07K16/4241—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an idiotypic determinant on Ig against anti-human or anti-animal Ig
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • G01N33/686—Anti-idiotype
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)

Abstract

La présente invention concerne des compositions et des procédés pour traiter un état pathologique ou une maladie sans l'utilisation de séquences de ciblage exogènes ou de compositions chimiques. La présente invention concerne des anticorps à domaine unique (sdAb), des protéines et des polypeptides comprenant les sdAb qui sont dirigés contre des composants intracellulaires qui provoquent un état pathologique ou une maladie. L'invention concerne également des acides nucléiques codant pour les sdAb, des protéines et des polypeptides, et des compositions comprenant les sdAb. L'invention comprend l'utilisation des compositions, des sdAb, et des acides nucléiques codant pour les sdAb à des fins prophylactiques, thérapeutiques ou diagnostiques.
PCT/US2015/057223 2014-10-23 2015-10-23 Anticorps à domaine unique dirigés contre des antigènes intracellulaires WO2016065323A2 (fr)

Priority Applications (33)

Application Number Priority Date Filing Date Title
LTEP15853465.1T LT3209685T (lt) 2014-10-23 2015-10-23 Antikūnai su vienu duomenu, nukreipti prieš viduląstelinius antigenus
KR1020177006630A KR101831123B1 (ko) 2014-10-23 2015-10-23 세포내 항원에 대해 지향된 단일 도메인 항체
PL15853465T PL3209685T3 (pl) 2014-10-23 2015-10-23 Przeciwciała jednodomenowe przeciwko antygenom wewnątrzkomórkowym
RS20190750A RS59063B1 (sr) 2014-10-23 2015-10-23 Antitela sa jednim domenom usmerena protiv intracelularnih antigena
EP19165430.0A EP3590962B1 (fr) 2014-10-23 2015-10-23 Anticorps à domaine unique dirigés contre les antigènes intracellulaires
CN201580056968.9A CN106852148B (zh) 2014-10-23 2015-10-23 针对细胞内抗原的单域抗体
DK15853465.1T DK3209685T3 (da) 2014-10-23 2015-10-23 Enkeltdomæneantistoffer rettet mod intracellulære antigener
AU2015335600A AU2015335600B2 (en) 2014-10-23 2015-10-23 Single domain antibodies directed against intracellular antigens
PL19165430T PL3590962T3 (pl) 2014-10-23 2015-10-23 Przeciwciała jednodomenowe przeciwko antygenom wewnątrzkomórkowym
SI201530789T SI3209685T1 (sl) 2014-10-23 2015-10-23 Enodomenska protitelesa, usmerjena proti intracelularnim antigenom
JP2017521577A JP2017538671A (ja) 2014-10-23 2015-10-23 細胞内抗原に対して指向された単一ドメイン抗体
ES15853465T ES2731876T3 (es) 2014-10-23 2015-10-23 Anticuerpos de dominio sencillo contra antígenos intracelulares
BR122020006918A BR122020006918B8 (pt) 2014-10-23 2015-10-23 Anticorpo de domínio único anti-stat3 e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
IL289769A IL289769B2 (en) 2014-10-23 2015-10-23 Monoclonal antibodies against intracellular antigens
EP21192390.9A EP4006052A1 (fr) 2014-10-23 2015-10-23 Anticorps à domaine unique dirigés contre les antigènes intracellulaires
RU2017116710A RU2017116710A (ru) 2014-10-23 2015-10-23 Однодоменные антитела, направленные против внутриклеточных антигенов
KR1020197026708A KR102207381B1 (ko) 2014-10-23 2015-10-23 세포내 항원에 대해 지향된 단일 도메인 항체
BR112017008165A BR112017008165B8 (pt) 2014-10-23 2015-10-23 anticorpo de domínio único direcionado contra um componente intracelular e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
EP15853465.1A EP3209685B1 (fr) 2014-10-23 2015-10-23 Anticorps à domaine unique dirigés contre des antigènes intracellulaires
BR122020006907A BR122020006907B8 (pt) 2014-10-23 2015-10-23 Anticorpo de domínio único anti-kras e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipetídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
MX2017003268A MX2017003268A (es) 2014-10-23 2015-10-23 Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares.
KR1020197026711A KR102207382B1 (ko) 2014-10-23 2015-10-23 세포내 항원에 대해 지향된 단일 도메인 항체
CA2962275A CA2962275C (fr) 2014-10-23 2015-10-23 Anticorps a domaine unique diriges contre des antigenes intracellulaires
BR122020006914A BR122020006914B8 (pt) 2014-10-23 2015-10-23 Anticorpo de domínio único anti-tnf-alfa e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
KR1020187004337A KR102023289B1 (ko) 2014-10-23 2015-10-23 세포내 항원에 대해 지향된 단일 도메인 항체
CN202010738353.7A CN111848793B (zh) 2014-10-23 2015-10-23 针对细胞内抗原的单域抗体
IL250961A IL250961B (en) 2014-10-23 2017-03-06 Monoclonal antibodies against intracellular antigens
HRP20191056TT HRP20191056T1 (hr) 2014-10-23 2019-06-12 Antitijela s jednom domenom usmjerena protiv intracelularnih antigena
AU2019204614A AU2019204614B2 (en) 2014-10-23 2019-06-28 Single domain antibodies directed against intracellular antigens
CY20191100706T CY1122035T1 (el) 2014-10-23 2019-07-03 Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων
AU2021200416A AU2021200416B2 (en) 2014-10-23 2021-01-22 Single domain antibodies directed against intracellular antigens
CY20211101082T CY1124867T1 (el) 2014-10-23 2021-12-09 Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων
AU2022204167A AU2022204167A1 (en) 2014-10-23 2022-06-15 Single domain antibodies directed against intracellular antigens

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201462067908P 2014-10-23 2014-10-23
US62/067,908 2014-10-23
US201562148656P 2015-04-16 2015-04-16
US62/148,656 2015-04-16
US201562188353P 2015-07-02 2015-07-02
US62/188,353 2015-07-02
US201562210795P 2015-08-27 2015-08-27
US62/210,795 2015-08-27

Publications (2)

Publication Number Publication Date
WO2016065323A2 WO2016065323A2 (fr) 2016-04-28
WO2016065323A3 true WO2016065323A3 (fr) 2016-06-16

Family

ID=55761757

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2015/057223 WO2016065323A2 (fr) 2014-10-23 2015-10-23 Anticorps à domaine unique dirigés contre des antigènes intracellulaires

Country Status (23)

Country Link
US (4) US9546211B2 (fr)
EP (3) EP4006052A1 (fr)
JP (5) JP2017538671A (fr)
KR (4) KR102023289B1 (fr)
CN (2) CN106852148B (fr)
AU (4) AU2015335600B2 (fr)
BR (4) BR122020006914B8 (fr)
CA (3) CA2962275C (fr)
CY (2) CY1122035T1 (fr)
DK (2) DK3209685T3 (fr)
ES (2) ES2900253T3 (fr)
HR (2) HRP20211889T1 (fr)
HU (2) HUE047601T2 (fr)
IL (2) IL289769B2 (fr)
LT (2) LT3209685T (fr)
MX (2) MX2017003268A (fr)
PL (2) PL3209685T3 (fr)
PT (2) PT3209685T (fr)
RS (2) RS62694B1 (fr)
RU (1) RU2017116710A (fr)
SI (2) SI3209685T1 (fr)
TW (1) TWI664289B (fr)
WO (1) WO2016065323A2 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180072815A1 (en) 2014-10-23 2018-03-15 Singh Biotechnology, Llc Single Domain Antibodies Directed Against Intracellular Antigens
US20170267784A1 (en) 2014-10-23 2017-09-21 Singh Molecular Medicine, Llc Single domain antibodies directed against intracellular antigens
DK3209685T3 (da) 2014-10-23 2019-07-29 Singh Molecular Medicine Llc Enkeltdomæneantistoffer rettet mod intracellulære antigener
AU2016239948B2 (en) 2015-03-31 2022-03-17 Sorriso Pharmaceuticals, Inc. Polypeptides
MX2018002586A (es) 2015-09-01 2020-11-24 First Wave Bio Inc Composiciones para usarse en el tratamiento de afecciones asociadas a una repsuesta inflamatoria anómala.
TWI746473B (zh) 2015-11-02 2021-11-21 美商辛分子醫藥有限公司 針對細胞內抗原之單域抗體
JP7080813B2 (ja) * 2015-12-10 2022-06-06 シティ・オブ・ホープ 細胞透過性のシアニド結合抗体
WO2018060453A1 (fr) 2016-09-30 2018-04-05 Vhsquared Limited Compositions
EP3596108A4 (fr) 2017-03-15 2020-12-23 Pandion Operations, Inc. Immunotolérance ciblée
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
TW201922780A (zh) 2017-09-25 2019-06-16 美商健生生物科技公司 以抗ｉｌ１２／ｉｌ２３抗體治療狼瘡之安全且有效之方法
US10174092B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
KR20190076354A (ko) * 2017-12-22 2019-07-02 주식회사 로피바이오 세포 내 침투능을 갖는 항 stat3 이중특이 항체를 포함하는, 염증성 질환 치료용 약학적 조성물
EP3730150A4 (fr) 2017-12-22 2021-10-06 Rophibio, Inc. Anticorps bispécifique anti-stat3 ayant une capacité de pénétration cellulaire, et composition pharmaceutique le contenant
WO2019213481A1 (fr) * 2018-05-04 2019-11-07 The Brigham And Women's Hospital, Inc. Méthodes et compositions pour le traitement d'une maladie ou d'un trouble inflammatoires
KR102101561B1 (ko) * 2018-07-25 2020-04-20 가톨릭대학교 산학협력단 신생혈관 표적용 조영제 조성물 및 이의 제조방법
JP2022533702A (ja) 2019-05-20 2022-07-25 パンディオン・オペレーションズ・インコーポレイテッド ＭＡｄＣＡＭ標的化免疫寛容
US20220242945A1 (en) 2019-06-21 2022-08-04 Sorriso Pharmaceuticals, Inc. Polypeptides
CA3144567A1 (fr) 2019-06-21 2020-12-24 Scott Crowe Polypeptides
CN110357965A (zh) * 2019-06-24 2019-10-22 浙江大学 一种突变型kras特异性抗体及其制备方法
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
EP4118098A1 (fr) 2020-03-11 2023-01-18 The Trustees of The University of Pennsylvania Procédés et composition pour administration de gènes à l'aide d'une particule virale modifiée
US10980756B1 (en) 2020-03-16 2021-04-20 First Wave Bio, Inc. Methods of treatment
CN115215939A (zh) * 2021-04-14 2022-10-21 中山大学 一种融合蛋白及其制备方法与应用
EP4366772A1 (fr) * 2021-07-07 2024-05-15 Singh Biotechnology, LLC Suppression d'uvéite par un anticorps à domaine unique
WO2023028589A2 (fr) * 2021-08-27 2023-03-02 Singh Biotechnology, Llc Anticorps thérapeutique à domaine unique
US11767366B1 (en) 2021-12-15 2023-09-26 Interius Biotherapeutics, Inc. Pseudotyped viral particles, compositions comprising the same, and uses thereof
WO2024003873A1 (fr) * 2022-06-30 2024-01-04 Intrexon Actobiotics Nv D/B/A Precigen Actobio Anticorps à domaine variable unique dirigés contre le facteur alpha de nécrose tumorale

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050226863A1 (en) * 2003-11-20 2005-10-13 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
US20100143371A1 (en) * 2006-10-31 2010-06-10 Zhenping Zhu Intrabodies

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5004697A (en) 1987-08-17 1991-04-02 Univ. Of Ca Cationized antibodies for delivery through the blood-brain barrier
DE69334095T2 (de) * 1992-07-17 2007-04-12 Dana-Farber Cancer Institute, Boston Verfahren zur intrazellulären Bindung von zielgerichteten Molekülen
FR2706486B1 (fr) * 1993-06-16 1995-09-01 Rhone Poulenc Rorer Sa Séquences nucléiques, vecteurs les contenant, compositions pharmaceutiques et utilisations thérapeutiques.
EP1204674A4 (fr) 1999-07-27 2005-06-01 Abgenix Inc Procedes et compositions permettant d'inhiber l'accumulation des polypeptides associee aux troubles neurologiques
US6277974B1 (en) * 1999-12-14 2001-08-21 Cogent Neuroscience, Inc. Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death
DE10019157A1 (de) 2000-04-18 2001-11-15 Stefan Duebel Verfahren zum Einbringen von Liganden in lebende Zellen
CA2441903C (fr) 2000-05-26 2012-07-31 National Research Council Of Canada Anticorps cibles sur le cerveau a domaine unique, derives d'anticorps de lama
US20040052762A1 (en) 2001-09-10 2004-03-18 Hua Yu Stat3 agonists and antagonists and therapeutic uses thereof
PL365758A1 (en) * 2000-12-29 2005-01-10 Savient Pharmaceuticals,Inc. Specific human antibodies for selective cancer therapy
WO2003077945A1 (fr) * 2002-03-14 2003-09-25 Medical Research Council Anticorps intracellulaires
GB0226727D0 (en) * 2002-11-15 2002-12-24 Medical Res Council Intrabodies
HUE026914T2 (en) * 2002-11-07 2016-08-29 Immunogen Inc Anti-CD33 antibodies and a method of treating acute myeloid leukemia
EP1558647B1 (fr) 2002-11-08 2015-06-10 Ablynx N.V. Anticorps a domaine unique diriges contre le facteur de necrose tumorale alpha et leurs utilisations
US20060034845A1 (en) 2002-11-08 2006-02-16 Karen Silence Single domain antibodies directed against tumor necrosis factor alpha and uses therefor
EP3299393A1 (fr) 2002-11-08 2018-03-28 Ablynx N.V. Anticorps à domaine unique dirigés contre le facteur alpha de la nécrose tumorale et leurs utilisations
GB0226729D0 (en) 2002-11-15 2002-12-24 Medical Res Council Intracellular antibodies
US7638122B2 (en) 2003-03-07 2009-12-29 University Of South Florida Stat3 antagonists and their use as vaccines against cancer
PL1888641T3 (pl) 2005-05-18 2012-05-31 Ablynx Nv Białka wiążące albuminę surowicy
DE102005023617A1 (de) 2005-05-21 2006-11-23 Aspre Ag Verfahren zum Mischen von Farben in einem Display
CA2588106A1 (fr) * 2007-05-18 2008-11-18 Nrc - Institute For Biological Sciences Anticorps a domaine unique et anticorps a chaines lourdes ciblant le recepteur du facteur de croissance epidermique et utilisations connexes
EP2008666A1 (fr) 2007-06-29 2008-12-31 Institut Pasteur Utilisation d'anticorps VHH pour la préparation de vecteurs de peptide pour fournir une substance d'intérêt et leurs applications
US20110195509A1 (en) 2007-09-06 2011-08-11 Drew Pardoll Treatment of th17-mediated autoimmune disease via inhibition of stat 3
WO2010001325A2 (fr) * 2008-06-30 2010-01-07 Silenseed Ltd Procédés, compositions et systèmes pour l’administration locale de médicaments
EP2143735A1 (fr) 2008-07-10 2010-01-13 Institut Pasteur Domaines variables d'anticorps de camélidé à chaîne lourde dirigés contre les protéines acides fibrillaires gliales
WO2010033913A1 (fr) * 2008-09-22 2010-03-25 Icb International, Inc. Anticorps, analogues et leurs utilisations
WO2011051327A2 (fr) 2009-10-30 2011-05-05 Novartis Ag Petites protéines à chaîne unique de type anticorps
WO2011163423A2 (fr) 2010-06-22 2011-12-29 University Of Central Florida Research Foundation, Inc. Procédés et compositions pour inhibiteur de stat3 capable de perméation cellulaire
JP6170940B2 (ja) * 2011-12-20 2017-07-26 アダエラータ、リミテッド パートナーシップＡｄａｅｒａｔａ， Ｌｉｍｉｔｅｄ Ｐａｒｔｎｅｒｓｈｉｐ Ｐｃｓｋ９の阻害剤としての単一ドメイン抗体
EP2920308B1 (fr) * 2012-10-31 2018-12-12 Ionis Pharmaceuticals, Inc. Traitement du cancer
CA2906740A1 (fr) * 2013-03-15 2014-09-18 Dana-Farber Cancer Institute, Inc. Peptides sos1 stabilises
US9802888B2 (en) * 2013-03-22 2017-10-31 University Of Hawaii STAT3 inhibitors
CN103368197B (zh) 2013-07-15 2015-11-25 国家电网公司 模块化多电平换流器的阀基控制设备和方法
CA2922698C (fr) 2013-08-29 2023-01-03 City Of Hope Conjugues penetrant dans les cellules comprenant des anticorps ne penetrant pas dans les cellules liees de maniere covalente a un ou plusieurs acides nucleiques de phosphorotioate
EP2873680A1 (fr) 2013-11-13 2015-05-20 F.Hoffmann-La Roche Ag Oligopeptide et procédés pour produire des conjugués de ceux-ci
EP2899208A1 (fr) 2014-01-28 2015-07-29 F.Hoffmann-La Roche Ag Anticorps à domaine unique de camélidés dirigés contre des protéines tau phosphorylées et procédés de production de conjugués de ceux-ci
DK3209685T3 (da) 2014-10-23 2019-07-29 Singh Molecular Medicine Llc Enkeltdomæneantistoffer rettet mod intracellulære antigener

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050226863A1 (en) * 2003-11-20 2005-10-13 Massachusetts Institute Of Technology Single-domain antibodies and uses thereof
US20100143371A1 (en) * 2006-10-31 2010-06-10 Zhenping Zhu Intrabodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SOMMER ET AL.: "Constitutively Active Mutant gp130 Receptor Protein from Inflammatory Hepatocellular Adenoma Is Inhibited by an Anti-gp130 Antibody That Specifically Neutralizes Interleukin 11 Signaling.", J BIO CHEM, vol. 287, no. 17, 20 April 2012 (2012-04-20), pages 13743 - 13751, XP055380778 *

Also Published As

Publication number Publication date
AU2021200416A1 (en) 2021-02-25
EP3590962A1 (fr) 2020-01-08
AU2019204614B2 (en) 2020-10-22
ES2900253T3 (es) 2022-03-16
HUE047601T2 (hu) 2020-05-28
MX2017003268A (es) 2017-08-02
US20160115247A1 (en) 2016-04-28
PT3209685T (pt) 2019-06-27
AU2015335600A1 (en) 2017-03-16
AU2015335600B2 (en) 2019-04-04
IL289769B1 (en) 2024-01-01
RU2017116710A (ru) 2018-11-23
CA3052777C (fr) 2021-06-01
PL3590962T3 (pl) 2022-01-31
JP2022037002A (ja) 2022-03-08
SI3590962T1 (sl) 2022-02-28
CA3052777A1 (fr) 2016-04-28
BR122020006918B1 (pt) 2022-03-15
JP6928773B2 (ja) 2021-09-01
TW201615834A (zh) 2016-05-01
BR122020006907B8 (pt) 2023-01-31
US20160115226A1 (en) 2016-04-28
PT3590962T (pt) 2021-12-15
LT3590962T (lt) 2021-12-27
KR102207382B1 (ko) 2021-01-27
CA3114318A1 (fr) 2016-04-28
IL250961B (en) 2022-02-01
KR102023289B1 (ko) 2019-09-19
US9695234B2 (en) 2017-07-04
US9546211B2 (en) 2017-01-17
CA2962275A1 (fr) 2016-04-28
KR101831123B1 (ko) 2018-02-22
JP7195400B2 (ja) 2022-12-23
DK3209685T3 (da) 2019-07-29
JP6986180B2 (ja) 2021-12-22
EP3209685A2 (fr) 2017-08-30
KR20170070002A (ko) 2017-06-21
JP2019142885A (ja) 2019-08-29
AU2021200416B2 (en) 2022-06-09
AU2022204167A1 (en) 2022-06-30
SI3209685T1 (sl) 2019-10-30
KR102207381B1 (ko) 2021-01-27
EP3590962B1 (fr) 2021-09-29
US20160115244A1 (en) 2016-04-28
HRP20191056T1 (hr) 2019-09-20
CN106852148B (zh) 2020-07-31
WO2016065323A2 (fr) 2016-04-28
US20160115248A1 (en) 2016-04-28
MX2021001098A (es) 2021-03-31
LT3209685T (lt) 2019-08-26
KR20180021205A (ko) 2018-02-28
JP6670963B2 (ja) 2020-03-25
US9663570B2 (en) 2017-05-30
ES2731876T3 (es) 2019-11-19
BR112017008165B1 (pt) 2020-04-22
TWI664289B (zh) 2019-07-01
KR20190107199A (ko) 2019-09-18
CY1122035T1 (el) 2020-10-14
IL250961A0 (en) 2017-04-30
HRP20211889T1 (hr) 2022-03-04
PL3209685T3 (pl) 2020-01-31
BR122020006914B1 (pt) 2022-03-22
IL289769A (en) 2022-03-01
KR20190108646A (ko) 2019-09-24
BR122020006907B1 (pt) 2022-03-22
DK3590962T3 (da) 2021-12-13
BR112017008165B8 (pt) 2020-10-27
BR112017008165A2 (pt) 2018-03-06
EP3209685A4 (fr) 2018-01-24
IL289769B2 (en) 2024-05-01
EP4006052A1 (fr) 2022-06-01
JP2017538671A (ja) 2017-12-28
CN111848793B (zh) 2023-08-18
RS59063B1 (sr) 2019-08-30
BR122020006918B8 (pt) 2023-01-31
EP3209685B1 (fr) 2019-04-24
JP2021165278A (ja) 2021-10-14
CN111848793A (zh) 2020-10-30
BR122020006914B8 (pt) 2023-01-31
AU2019204614A1 (en) 2019-07-18
CY1124867T1 (el) 2022-11-25
RS62694B1 (sr) 2022-01-31
CA2962275C (fr) 2019-11-05
JP2020015732A (ja) 2020-01-30
CN106852148A (zh) 2017-06-13
HUE057605T2 (hu) 2022-06-28

Similar Documents

Publication Publication Date Title
WO2016065323A3 (fr) Anticorps à domaine unique dirigés contre des antigènes intracellulaires
PH12019500709A1 (en) Anti-lag-3 antibodies and methods of use thereof
WO2017136820A3 (fr) Technologie fit-immunoglobuline et ses utilisations
MX2022001222A (es) Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y metodos para usarlos.
PH12018500233A1 (en) Single domain antibody programmed death-ligand (pd-l1) and derived protein thereof
WO2017079314A3 (fr) Anticorps à domaine unique dirigés contre des antigènes intracellulaires
WO2016191643A3 (fr) Agents de liaison à tigit et leurs utilisations
WO2018017864A3 (fr) Agents de liaison à pvrig et leurs utilisations
EP3486256A3 (fr) Anticorps et fragments de liaison à l'antigène qui se lient spécifiquement à la protéine tau associée aux microtubules
WO2015112886A3 (fr) Protéines de liaison et leurs procédés d'utilisation
WO2016098079A3 (fr) Compositions et méthodes associées à des anticorps ciblant bmp6
WO2015164392A3 (fr) Nouveaux anticorps antii-rnf43 et méthodes d'utilisation
EP4339615A3 (fr) Anticorps anti-pd-1
WO2015132675A3 (fr) Procédés et compositions pour modifier une réponse immunitaire
WO2018075692A3 (fr) Constructions d'anticorps
WO2016020882A3 (fr) Anticorps de type angiopoétine 4 (angptl4) et procédés d'utilisation
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
EA202091567A1 (ru) Химерные белки мти
WO2019094533A8 (fr) Agents de liaison à angptl8 et leurs méthodes d'utilisation
WO2017019957A3 (fr) Protéines de liaison et leurs procédés d'utilisation
WO2014151834A3 (fr) Procédés et compositions liés aux protéines de liaison à un antigène anti-ccr7
WO2016075305A3 (fr) Peptides dérivés d'acinetobacter baumannii et leur utilisation en vaccination
WO2016120489A3 (fr) Vecteurs lentiviraux pour l'expression d'antigènes de mycobacterium tuberculosis
WO2016040767A3 (fr) Anticorps et épitopes chrdl-1

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15853465

Country of ref document: EP

Kind code of ref document: A2

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 250961

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 20177006630

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2017/003268

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2015335600

Country of ref document: AU

Date of ref document: 20151023

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2962275

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2017521577

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 122020006925

Country of ref document: BR

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2015853465

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2017116710

Country of ref document: RU

Kind code of ref document: A

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112017008165

Country of ref document: BR

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15853465

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 112017008165

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20170419